These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9130310)

  • 1. Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated.
    Weiner I; Tarrasch R; Bernasconi E; Broersen LM; Rüttimann TC; Feldon J
    Pharmacol Biochem Behav; 1997 Apr; 56(4):817-26. PubMed ID: 9130310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus.
    Ruob C; Elsner J; Weiner I; Feldon J
    Behav Brain Res; 1997 Oct; 88(1):35-41. PubMed ID: 9401706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus.
    Weiner I; Bernasconi E; Broersen LM; Feldon J
    Behav Pharmacol; 1997 Oct; 8(5):442-57. PubMed ID: 9832983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs.
    Weiner I; Shadach E; Barkai R; Feldon J
    Neuropsychopharmacology; 1997 Jan; 16(1):42-50. PubMed ID: 8981387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.
    Weiner I; Shadach E; Tarrasch R; Kidron R; Feldon J
    Biol Psychiatry; 1996 Nov; 40(9):834-43. PubMed ID: 8896769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol-induced potentiation of latent inhibition: interaction with parameters of conditioning.
    Ruob C; Weiner I; Feldon J
    Behav Pharmacol; 1998 May; 9(3):245-53. PubMed ID: 9832938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride.
    Trimble KM; Bell R; King DJ
    Pharmacol Biochem Behav; 1997 Apr; 56(4):809-16. PubMed ID: 9130309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphetamine increases aversive conditioning to diffuse contextual stimuli and to a discrete trace stimulus when conditioned at higher footshock intensity.
    Norman C; Cassaday HJ
    J Psychopharmacol; 2003 Mar; 17(1):67-76. PubMed ID: 12680741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sigma ligand BMY-14802 as a potential antipsychotic: evidence from the latent inhibition model in rats.
    Weiner I; Traub A; Rawlins JN; Smith AD; Feldon J
    Behav Pharmacol; 1995 Jan; 6(1):46-54. PubMed ID: 11224311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.
    Killcross AS; Dickinson A; Robbins TW
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):185-95. PubMed ID: 7862894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.
    Weiner I; Schiller D; Gaisler-Salomon I
    Neuropsychopharmacology; 2003 Mar; 28(3):499-509. PubMed ID: 12629529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.
    Weiner I; Lubow RE; Feldon J
    Psychopharmacology (Berl); 1984; 83(2):194-9. PubMed ID: 6431473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia.
    Weiner I; Feldon J
    Pharmacol Biochem Behav; 1992 Aug; 42(4):625-31. PubMed ID: 1513845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans.
    Salgado JV; Hetem LA; Vidal M; Graeff FG; Danion JM; Sandner G
    Behav Brain Res; 2000 Dec; 117(1-2):61-7. PubMed ID: 11099758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of latent inhibition to a contextual stimulus with systemic amphetamine.
    Norman C; Cassaday HJ
    Neurobiol Learn Mem; 2004 Jul; 82(1):61-4. PubMed ID: 15183172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abolition of the acquisition but not the expression of latent inhibition by chlordiazepoxide in rats.
    Feldon J; Weiner I
    Pharmacol Biochem Behav; 1989 Jan; 32(1):123-7. PubMed ID: 2734324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.
    Russig H; Murphy CA; Feldon J
    Neuropsychopharmacology; 2002 Jun; 26(6):765-77. PubMed ID: 12007747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice.
    Chang T; Meyer U; Feldon J; Yee BK
    Psychopharmacology (Berl); 2007 Apr; 191(2):211-21. PubMed ID: 17180617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The D1 agonist SKF 38393 attenuates amphetamine-produced enhancement of responding for conditioned reward in rats.
    Ranaldi R; Pantalony D; Beninger RJ
    Pharmacol Biochem Behav; 1995 Sep; 52(1):131-7. PubMed ID: 7501655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of apomorphine and clozapine on conditioned freezing and latent inhibition.
    Masson S; Avanzi V; Troncoso AC; Brandão ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):935-43. PubMed ID: 14499310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.